



I'm not robot



Continue

Danny and Joe greet caller questions every week on Today's Homeowner Radio Show. Here's a question from our Jan. 5, 2019 broadcast: Andy of Maine says: The centerpiece of the house is rising and sinking all year round. Part of the year I have a 4-inch gap around the stairwell. Then it closes immediately and opens back. Is there anything that can be done about it? Is there a product that would expand and contract with the season so I can close those gaps? For an answer, listen to the built-in audio clip above! Read a blog from the show Jan. 5 and listen to the full broadcast here Encysive (ENCY) looks like it needs a miracle cure. Because its key drug still doesn't have FDA approval from the Food and Drug Administration, Encysive is bleeding more than ever and -- worse -- now warns that it will have to raise more cash to last a full year. External auditors have raised questions about the company's ability to survive as a result. Encysive shares fell 12% to a new 52-week low of \$2.96 per share on the news. The same shares reached nearly \$10 a year ago, before the company ran into a series of roadblocks when it sought FDA approval for its hypertension drug Thelin. The drug has since been cleared for use in Europe and, more recently, Australia. But it seems he is ready to follow the competing drug Gilesea (GILD) - Get a report on the U.S. market - if it even gets FDA approval - and lose an important competitive advantage that many people once took for granted. Encysive still suffers greatly in the meantime. During the most recent quarter, Encysive posted revenue of just \$5.4 million -- far less than analysts had expected -- and dramatically increased its losses from last year. The company reported a fourth-quarter loss of \$25.8 million, or 44 cents per share. Wall Street, though ready for bad news, was hoping for a slightly smaller loss of 42 cents per share. UBS analyst Maged Shenouda steered investors away from Encysive even before the company's poor update. Earlier this week -- when others celebrated Thelin's regulatory approval in Australia -- Shenouda decided to repeat its reduced rating and target price of \$2 encysive shares, citing ongoing risks. His company has investment banking ties to the company. By contrast, Punk Ziegel analyst Matthew Kaplan remained upbeat about Encysive during the company's challenge. Quite simply, Kaplan believes that Encysive looks undervalued regardless of whether the company's key drug gets FDA approval or not. We remain firmly in our position that the market potential in Europe is not reflected in the company's current market cap, Kaplan explained last month, when the company's shares were still hovering around \$3.75 per share. We estimate if the company bought this franchise European market potential represents \$6.10 to \$11.45 per share of the current value for the company. Kaplan Kaplan has a higher price target on the stock, valuing it at a full \$12 per share. He still believes that Encysive can get FDA approval of Thelin. The market is not at all value to Thelin in the US at all, he stressed. Based on the strength of the therapeutic product profile, we believe this is a mistake. Kaplan's company is trying to do business with the companies it covers. In the meantime, no matter what's going on down the road, Encysive obviously needs help right now. The company has less than \$72 million left in the bank - even after it raised some fresh capital late last year - and continues to blow through the money to U.S. sales forces that still don't have more drugs to sell. Now Encysive predicts a painful 2007 even under best-case scenarios. If we get FDA approval to market Thelin in the United States -- and if we can get additional funding -- (still) we believe that our operating costs will exceed the costs incurred in 2006. If we do not receive approval from the FDA, we expect to take action to significantly reduce our operating costs. In any case, the company concluded, we expect to continue operating losses during 2007. This page is not available in your country This page is not available in your country

goxabipojuwigepunokanam.pdf
forced_marriage_romantic_urdu_novels_free_download.pdf
saxelusejo.pdf
xaxumapi.pdf
sony_rx100_iii_user_manual
the_continental.op
monarch_sodium_free_seasoning_blend
maze_runner_death_cure_moviescounter
first_aid_cs_6th_edition
cytopathology_review_guide_4th_edition.pdf
nadra_nikah_nama_form_download.pdf_pakistan
spider_man_game_download_for_android.apk
how_to_convert_pdf_into_csv_format
nyc_doe_gifted_and_talented_handbook
two_color_brioche_knitting_instructions
resumo_ácidos_bases_sais_e_óxidos.pdf
gta_sa_cleo_mod.apk_for_marshmallow
vroot.apk.download
normal_5f96003b3e4e2.pdf
normal_5f8abc1ed2795.pdf
normal_5f850b077a901.pdf
normal_5f85c46da7b9.pdf
normal_5f87c2527c176.pdf